Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients.
CD34
Leukapheresis
Multiple myeloma
Peripheral blood stem cells
Stem cell collection
Stem cell mobilization
Journal
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie
ISSN: 1660-3796
Titre abrégé: Transfus Med Hemother
Pays: Switzerland
ID NLM: 101176417
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
30
12
2022
accepted:
06
03
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
High-dose chemotherapy (HDCT) followed by autologous blood stem-cell transplantation (ABSCT) remains the standard consolidation therapy for newly diagnosed eligible multiple myeloma (MM) patients. As a prerequisite, peripheral blood stem cells (PBSCs) must be mobilized and collected by leukapheresis (LP). Many factors can hamper PBSC mobilization/collection. Here, we provide a comprehensive multiparametric assessment of PBSC mobilization/collection outcome parameters in a large cohort. In total, 790 MM patients (471 [60%] male, 319 [40%] female) who underwent PBSC mobilization/collection during first-line treatment were included. Evaluated PBSC mobilization/collection outcome parameters included the prolongation of PBSC mobilization, plerixafor administration, number of LP sessions, and overall PBSC collection goal/result. 741 (94%) patients received cyclophosphamide/adriamycin/dexamethasone (CAD) and granulocyte-colony-stimulating factor (G-CSF) mobilization. Plerixafor was administered in 80 (10%) patients. 489 (62%) patients started LP without delay. 530 (67%) patients reached the PBSC collection goal at the first LP session. The mean overall PBSC collection result was 10.3 (standard deviation [SD] 4.4) × 10 Considering the identified risk factors in the clinical setting can contribute to optimized PBSC mobilization/collection. Moreover, our study demonstrates the necessity for a differentiated evaluation of PBSC mobilization/collection outcome parameters.
Identifiants
pubmed: 37899996
doi: 10.1159/000530056
pii: 530056
pmc: PMC10601599
doi:
Types de publication
Journal Article
Langues
eng
Pagination
382-395Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Sandra Sauer: travel grants or honoraria for presentations for Celgene, BMS, Janssen, Takeda, and Amgen. Lennart Hieke, Juliane Brandt, and Carsten Müller-Tidow: none. Anita Schmitt: received travel grants from Hexal and Jazz Pharmaceuticals, research grant from Therakos/Mallinckrodt, consultant by Janssen-Cilag and BMS, and is a cofounder of TolerogenixX Ltd. AS is a parttime employee of TolerogenixX Ltd. Joseph Kauer: honoraria Astra Zeneca. Katharina Kriegsmann: advisory board Sanofi; research funding Sanofi, BMS.
Références
Leukemia. 2008 Jun;22(6):1282-4
pubmed: 18216870
N Engl J Med. 1996 Jul 11;335(2):91-7
pubmed: 8649495
Transplant Cell Ther. 2021 Oct;27(10):876.e1-876.e11
pubmed: 34214737
Bone Marrow Transplant. 2001 May;27(9):925-31
pubmed: 11436102
Transfusion. 2014 Feb;54(2):331-9
pubmed: 23781769
Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):402-409
pubmed: 32792260
Int J Hematol. 2013 Apr;97(4):446-55
pubmed: 23420184
Transfus Apher Sci. 2012 Dec;47(3):331-5
pubmed: 22874435
N Engl J Med. 2003 Dec 25;349(26):2495-502
pubmed: 14695409
Stem Cell Res Ther. 2015 Apr 17;6:64
pubmed: 25889496
Leuk Lymphoma. 2013 Oct;54(10):2200-4
pubmed: 23387937
Hematol Transfus Cell Ther. 2019 Oct - Dec;41(4):285-291
pubmed: 31412990
Biol Blood Marrow Transplant. 2013 May;19(5):760-6
pubmed: 23298856
Transplant Cell Ther. 2021 Aug;27(8):661.e1-661.e6
pubmed: 33895403
J Clin Apher. 2010;25(5):280-6
pubmed: 20623783
Leukemia. 2007 Jun;21(6):1294-9
pubmed: 17377586
J Clin Apher. 2018 Feb;33(1):29-37
pubmed: 28556233
Transfus Med. 2017 Feb;27(1):36-42
pubmed: 27726235
J Clin Apher. 2011;26(3):111-5
pubmed: 21647951
Bone Marrow Transplant. 2011 Jan;46(1):59-63
pubmed: 20421869
Transfus Apher Sci. 2020 Feb;59(1):102595
pubmed: 31492570
Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23
pubmed: 19450756
Hematol Oncol. 2015 Sep;33(3):125-32
pubmed: 24890497
Bone Marrow Transplant. 2013 Aug;48(8):1033-9
pubmed: 23334269
Vox Sang. 2014 Nov;107(4):407-15
pubmed: 25130876
Oncol Lett. 2020 Jan;19(1):1051-1059
pubmed: 31897218
Leuk Lymphoma. 2019 Sep;60(9):2199-2206
pubmed: 30845862
Blood. 2009 Aug 27;114(9):1729-35
pubmed: 19561323
Transplant Cell Ther. 2021 Mar;27(3):244.e1-244.e8
pubmed: 33781522
Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2
pubmed: 18033320
J Clin Oncol. 2012 Aug 20;30(24):2946-55
pubmed: 22802322
Transfus Apher Sci. 2009 Aug;41(1):33-7
pubmed: 19540167
J Clin Apher. 2012;27(2):64-74
pubmed: 22298390
Leukemia. 2015 Aug;29(8):1721-9
pubmed: 25787915
Leukemia. 2007 Sep;21(9):2035-42
pubmed: 17581613
Transfus Apher Sci. 2008 Dec;39(3):187-92
pubmed: 19036640
Bone Marrow Transplant. 2014 Jul;49(7):865-72
pubmed: 24686988
Bone Marrow Transplant. 2014 Jun;49(6):744-50
pubmed: 24637898
Bone Marrow Transplant. 2012 Apr;47(4):488-93
pubmed: 21572461
Blood. 2018 Sep 13;132(11):1114-1124
pubmed: 29967130
J Clin Oncol. 2010 Dec 10;28(35):e741-3; author reply e744-5
pubmed: 21060027
Lancet Haematol. 2022 Nov;9(11):e810-e821
pubmed: 36328040
Biol Blood Marrow Transplant. 2020 Sep;26(9):1589-1596
pubmed: 32428735
Biol Blood Marrow Transplant. 2010 Apr;16(4):490-9
pubmed: 19925876
Curr Opin Hematol. 2013 Nov;20(6):485-93
pubmed: 24104408
N Engl J Med. 2003 May 8;348(19):1875-83
pubmed: 12736280
Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9
pubmed: 23186983
BMC Cancer. 2019 May 28;19(1):504
pubmed: 31138244
Front Oncol. 2015 Feb 18;5:40
pubmed: 25741475
Biol Blood Marrow Transplant. 2018 Jun;24(6):1281-1288
pubmed: 29353110